JF already knows the value of DEP cabazitaxel - she has had enough discussions with interested parties and the trials are not closed or randomised. The company just carries on regardless of the current SP and we all have to wait for the results.
Meanwhile there has been no more notices of changes of substantial holdings, even with the huge amount of buying and selling.
JF and NB are both in the list of top twenty holders.
And the annual report has come out one week earlier than normal. I wonder why?
Ann: App 4E/Annual Report to shareholders, page-17
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
